| 23.03 -0.21 (-0.9%) | 04-22 15:43 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 32.21 | 1-year : | 37.07 |
| Resists | First : | 27.58 | Second : | 31.73 |
| Pivot price | 23.89 |
|||
| Supports | First : | 20.85 | Second : | 17.34 |
| MAs | MA(5) : | 23.52 |
MA(20) : | 24.78 |
| MA(100) : | 30.85 |
MA(250) : | 31.57 |
|
| MACD | MACD : | -1 |
Signal : | -1 |
| %K %D | K(14,3) : | 38.1 |
D(3) : | 33.2 |
| RSI | RSI(14): 42.4 | |||
| 52-week | High : | 59.22 | Low : | 9.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HROW ] has closed above bottom band by 31.9%. Bollinger Bands are 53% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 23.98 - 24.1 | 24.1 - 24.21 |
| Low: | 22.51 - 22.66 | 22.66 - 22.8 |
| Close: | 22.97 - 23.2 | 23.2 - 23.43 |
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Fri, 28 Mar 2025
Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha
Fri, 28 Mar 2025
Harrow Health (HROW) Gets a Buy from Craig-Hallum - The Globe and Mail
Fri, 28 Mar 2025
Earnings call transcript: Harrow Health Q4 2024 earnings beat forecasts - Investing.com
Thu, 27 Mar 2025
Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Mon, 24 Mar 2025
TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan
Mon, 17 Mar 2025
Harrow Slashes VEVYE Dry Eye Treatment to $59: No Insurance Hurdles, Money-Back Guarantee - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 36 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 13.4 (%) |
| Held by Institutions | 59 (%) |
| Shares Short | 2,920 (K) |
| Shares Short P.Month | 2,730 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.96 |
| Profit Margin | -8.8 % |
| Operating Margin | 19.6 % |
| Return on Assets (ttm) | 1.6 % |
| Return on Equity (ttm) | -25.1 % |
| Qtrly Rev. Growth | 83.8 % |
| Gross Profit (p.s.) | 4.21 |
| Sales Per Share | 5.59 |
| EBITDA (p.s.) | 0.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -53 (M) |
| PE Ratio | -47.43 |
| PEG Ratio | 0 |
| Price to Book value | 11.85 |
| Price to Sales | 4.15 |
| Price to Cash Flow | -37.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|